Humoral Immune Response to AAV

Area of Science:

• Virology
• Immunology
• Gene Therapy

Background:

• Adeno-associated virus (AAV) is a parvovirus widely used in gene therapy due to its safety and transduction capabilities.
• Natural AAV infections are common, leading to widespread pre-existing antibodies in humans and animals.
• These antibodies can significantly impact AAV vector safety and therapeutic efficacy.

Purpose of the Study:

• To review antibody responses to natural AAV infections and gene therapy vectors.
• To analyze the impact of these antibodies on AAV vector-based gene therapy clinical development.
• To discuss methods for AAV antibody detection and strategies to mitigate their effects.

Main Methods:

• Literature review of studies on AAV infections, antibody responses, and gene therapy.
• Analysis of existing data on AAV antibody detection methods.
• Synthesis of strategies to overcome antibody-mediated neutralization in gene therapy.

Main Results:

• Pre-existing AAV antibodies can block vector transduction and alter biodistribution.
• Antibody responses vary depending on the AAV serotype and exposure route.
• Current detection methods for AAV antibodies have limitations.

Conclusions:

• Understanding and managing pre-existing AAV antibodies is critical for successful gene therapy.
• Development of effective strategies to overcome antibody barriers is essential for advancing AAV-based therapies.
• Further research into antibody detection and immune modulation is warranted.